344 related articles for article (PubMed ID: 21522029)
21. Future of convection-enhanced delivery in the treatment of brain tumors.
Bidros DS; Liu JK; Vogelbaum MA
Future Oncol; 2010 Jan; 6(1):117-25. PubMed ID: 20021213
[TBL] [Abstract][Full Text] [Related]
22. Does chemotherapy benefit the patient with a central nervous system glioma?
Rodriguez LA; Levin VA
Oncology (Williston Park); 1987 Nov; 1(9):29-36, 40-1. PubMed ID: 3079493
[TBL] [Abstract][Full Text] [Related]
23. Trabedersen, a TGFbeta2-specific antisense oligonucleotide for the treatment of malignant gliomas and other tumors overexpressing TGFbeta2.
Vallières L
IDrugs; 2009 Jul; 12(7):445-53. PubMed ID: 19579166
[TBL] [Abstract][Full Text] [Related]
24. Novel approaches to glioma drug design and drug screening.
Patil SA; Hosni-Ahmed A; Jones TS; Patil R; Pfeffer LM; Miller DD
Expert Opin Drug Discov; 2013 Sep; 8(9):1135-51. PubMed ID: 23738794
[TBL] [Abstract][Full Text] [Related]
25. Therapy for recurrent malignant glioma in adults.
Mrugala MM; Kesari S; Ramakrishna N; Wen PY
Expert Rev Anticancer Ther; 2004 Oct; 4(5):759-82. PubMed ID: 15485312
[TBL] [Abstract][Full Text] [Related]
26. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.
Wen PY; Yung WK; Lamborn KR; Dahia PL; Wang Y; Peng B; Abrey LE; Raizer J; Cloughesy TF; Fink K; Gilbert M; Chang S; Junck L; Schiff D; Lieberman F; Fine HA; Mehta M; Robins HI; DeAngelis LM; Groves MD; Puduvalli VK; Levin V; Conrad C; Maher EA; Aldape K; Hayes M; Letvak L; Egorin MJ; Capdeville R; Kaplan R; Murgo AJ; Stiles C; Prados MD
Clin Cancer Res; 2006 Aug; 12(16):4899-907. PubMed ID: 16914578
[TBL] [Abstract][Full Text] [Related]
27. Small molecule inhibitors in children with malignant gliomas.
Herrington B; Kieran MW
Pediatr Blood Cancer; 2009 Sep; 53(3):312-7. PubMed ID: 19434732
[TBL] [Abstract][Full Text] [Related]
28. Evidence that Cereport's ability to increase permeability of rat gliomas is dependent upon extent of tumor growth: implications for treating newly emerging tumor colonies.
Bartus RT; Snodgrass P; Dean RL; Kordower JH; Emerich DF
Exp Neurol; 2000 Jan; 161(1):234-44. PubMed ID: 10683290
[TBL] [Abstract][Full Text] [Related]
29. Emerging drugs for malignant glioma.
Mason WP
Expert Opin Emerg Drugs; 2008 Mar; 13(1):81-94. PubMed ID: 18321150
[TBL] [Abstract][Full Text] [Related]
30. Targeting core (mutated) pathways of high-grade gliomas: challenges of intrinsic resistance and drug efflux.
Lin F; de Gooijer MC; Hanekamp D; Brandsma D; Beijnen JH; van Tellingen O
CNS Oncol; 2013 May; 2(3):271-88. PubMed ID: 25054467
[TBL] [Abstract][Full Text] [Related]
31. The challenges and the promise of molecular targeted therapy in malignant gliomas.
Wang H; Xu T; Jiang Y; Xu H; Yan Y; Fu D; Chen J
Neoplasia; 2015 Mar; 17(3):239-55. PubMed ID: 25810009
[TBL] [Abstract][Full Text] [Related]
32. Polymersomes as an effective drug delivery system for glioma--a review.
Krishnamoorthy B; Karanam V; Chellan VR; Siram K; Natarajan TS; Gregory M
J Drug Target; 2014 Jul; 22(6):469-77. PubMed ID: 24830300
[TBL] [Abstract][Full Text] [Related]
33. Cytotoxic and molecular chemotherapy for high-grade glioma: an emerging strategy for the future.
Cavaliere R; Newton H
Expert Opin Pharmacother; 2006 Apr; 7(6):749-65. PubMed ID: 16556090
[TBL] [Abstract][Full Text] [Related]
34. Recent advances in the molecular genetics of malignant gliomas disclose targets for antitumor agent perillyl alcohol.
da Fonseca CO; Landeiro JA; Clark SS; Quirico-Santos T; da Costa Carvalho Mda G; Gattass CR
Surg Neurol; 2006; 65 Suppl 1():S1:2-1:8; discussion S1:8-1:9. PubMed ID: 16427438
[TBL] [Abstract][Full Text] [Related]
35. Valproic acid for the treatment of malignant gliomas: review of the preclinical rationale and published clinical results.
Berendsen S; Broekman M; Seute T; Snijders T; van Es C; de Vos F; Regli L; Robe P
Expert Opin Investig Drugs; 2012 Sep; 21(9):1391-415. PubMed ID: 22668241
[TBL] [Abstract][Full Text] [Related]
36. Peptide-based glioma-targeted drug delivery vector gHoPe2.
Eriste E; Kurrikoff K; Suhorutšenko J; Oskolkov N; Copolovici DM; Jones S; Laakkonen P; Howl J; Langel Ü
Bioconjug Chem; 2013 Mar; 24(3):305-13. PubMed ID: 23350661
[TBL] [Abstract][Full Text] [Related]
37. The chemokine network, a newly discovered target in high grade gliomas.
Domanska UM; Kruizinga RC; den Dunnen WF; Timmer-Bosscha H; de Vries EG; Walenkamp AM
Crit Rev Oncol Hematol; 2011 Aug; 79(2):154-63. PubMed ID: 20709564
[TBL] [Abstract][Full Text] [Related]
38. The blood-brain/tumor barriers: challenges and chances for malignant gliomas targeted drug delivery.
Zhan C; Lu W
Curr Pharm Biotechnol; 2012 Sep; 13(12):2380-7. PubMed ID: 23016643
[TBL] [Abstract][Full Text] [Related]
39. Pharmacogenomics of brain cancer and personalized medicine in malignant gliomas.
Shai RM; Reichardt JK; Chen TC
Future Oncol; 2008 Aug; 4(4):525-34. PubMed ID: 18684063
[TBL] [Abstract][Full Text] [Related]
40. Current and future directions for Phase II trials in high-grade glioma.
Alexander BM; Lee EQ; Reardon DA; Wen PY
Expert Rev Neurother; 2013 Apr; 13(4):369-87. PubMed ID: 23545053
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
